
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Revised guidelines help evaluate the child who doesn't meet all the classic criteria for KD and provide a framework for long-term management based on the risk of myocardial infarction.






